Astragaloside IV improved oxidative stress-mediated endothelial dysfunction relevant to cardiovascular diseases through several mechanisms: preventing the uncoupling of endothelial nitric oxide synthase (eNOS), increasing eNOS and nitric oxide (NO), and enhancing several activating enzymes to activate the antioxidant system [70]. The gene discussed is NOS3; the disease is cardiovascular disorder.